Navigation Links
HIV-infected adults in Botswana respond positively to ARV therapy public treatment program

With preliminary results from a study in Botswana, Harvard School of Public Health researchers have found that people with HIV-1 subtype C in resource-poor settings, who receive antiretroviral (ARV) therapy, can achieve comparable results to those in the developed world. A fully supported health care delivery system and infrastructure help ensure this success, according to data published in November 2005 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS).

More than 95 percent of HIV-infected people live in resource-poor nations -- and only a fraction of the people have access to the potentially lifesaving treatment. This study evaluated the effectiveness of combination ARV treatment in decreasing HIV disease and death. With more than one year of follow-up for clinical and laboratory outcomes and two years of follow-up for survival estimates, the majority of enrolled patients on ARV treatment experienced favorable clinical outcomes, including improved CD4 counts, decreased viral load and weight gain comparable with other successful care and treatment programs in the developed world.

"This data confirms what we are starting to see throughout the developing world. Patients will do fine regardless of social and economic status, provided the necessary infrastructure and funding are in place," said Richard Marlink, M.D., senior author of the article and professor in the Department of Immunology and Infectious Diseases at Harvard School of Public Health (HSPH).

The clinical data was collected from a public-private partnership between the Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education (BHP) and the Infectious Disease Care Clinic (IDCC) at Princess Marina Hospital and funded through Bristol-Myers Squibbs' Secure the Future initiative. Initiated in April 2001, this public sector treatment program led to the development of the Botswana's national program and provided the first clinica
'"/>

Source:Harvard School of Public Health


Page: 1 2

Related biology news :

1. Zinc supplements safe for HIV-infected children
2. Low-cost drug gaining favor for use in HIV-infected children in poor countries
3. New study shows benefit of early therapy in HIV-infected infants
4. Meth promotes spread of virus in HIV-infected users
5. H5N1 avian flu virus vaccine induces immune responses in healthy adults
6. Confidence in memory performance helps older adults remember
7. Genes affecting blood pressure change as children become adults
8. Suicide risk does not increase when adults start using antidepressants, study finds
9. One-third of adults with diabetes still dont know they have it
10. Sleep deprivation doubles risks of obesity in both children and adults
11. Brain regions do not communicate efficiently in adults with autism
Post Your Comments:
(Date:8/20/2008)...nta, Ga. August 20, 2008) Today, the U.S. Environ... of a $2 million grant to the University of Kentuc... nanoparticles affect their ability to enter the b...Results (STAR) grant ever awarded to the Universit...ever awarded by EPA STAR for nanotechnology resear...
(Date:8/20/2008)...AKERS are supposed to protect people from heart at... as well as biological security. , Earlier this y...al School demonstrated how a commercial radio tran...tions from a pacemaker ( New Scientist, 22 March,...tor and adjust the implanted device, but a malicio...
(Date:8/20/2008)...entre for Addiction and Mental Health (CAMH) is pr...on by the Canada Foundation for Innovation (CFI) i...ntervention, treatment and prevention of mental il...e. , This funding from the Large-Scale Institut...tal Fund will allow CAMH to leverage our scientifi...
(Date:8/20/2008)...COLUMBUS, Ohio -- Researchers here have found a wa...gen very efficiently. , A new catalyst makes hyd...kable temperature, and using inexpensive ingredien...olecular engineering at Ohio State University, sai...n others being developed around the world, because...
Breaking Biology News(10 mins):$2M grant awarded to University of Kentucky for research on nanoparticles and human health 2How to stop a new type of heart attack 2Large-scale investment catapults CAMH's mental illness and addiction research forward 2A better way to make hydrogen from biofuels 2A better way to make hydrogen from biofuels 3Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 1Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 2Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 3Susan G Komen For The Cure Karmanos Cancer Institute Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Inci 4421 4Oncolytics Biotech Inc Announces Approval for U K Clinical Trial Investigating REOLYSIN 28R 29 in Combination with Cyclophosphamide 1450 1Oncolytics Biotech Inc Announces Approval for U K Clinical Trial Investigating REOLYSIN 28R 29 in Combination with Cyclophosphamide 1450 2Oncolytics Biotech Inc Announces Approval for U K Clinical Trial Investigating REOLYSIN 28R 29 in Combination with Cyclophosphamide 1450 3Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non Hodgkins Lymphoma 621 1Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non Hodgkins Lymphoma 621 2Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non Hodgkins Lymphoma 621 3Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non Hodgkins Lymphoma 621 4Tracleer 28R 29 Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 619 1Tracleer 28R 29 Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 619 2Tracleer 28R 29 Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 619 3
...stration (FDA) today announced a series of importa...steroidal anti-inflammatory class of drugs, includ...ription (over-the-counter (OTC)) non-selective NSA...ble on the Internet at http://www.fda.gov/cder/dru...otect and advance the health of the millions of Am...
...Polytechnique Fédérale de Lausanne (EPFL) in Switz...ce to silence a mutated gene that causes inherited...tantially delaying both the onset and the progress...results will be published in the April issue of Na...e publication March 13. , In addition to silencing...
...stitute researchers chiseling away at the problem ...nation of how the drugs, main cellular target in b...se medications. The findings are already leading t...neered to circumvent resistance, which is a major ...z, a Howard Hughes Medical Institute investigator ...
...first time mapped multiple complex biological inte...m, enhancing our understanding of how the networks...uence one another. New research published in the O...uch maps can also reveal cryptic interactions and ...t haven,t been observed experimentally. , A living...
Other Biology News:FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 2Silence the gene, save the cell: RNA interference as promising therapy for ALS 2Silence the gene, save the cell: RNA interference as promising therapy for ALS 3Researchers make gains in understanding antibiotic resistance 2Researchers make gains in understanding antibiotic resistance 3Navigating an integrated yeast network 2
(Date:8/21/2008)... NEW YORK, MUNICH, Germany and AMSTERDAM, Neth...thcare and SpePharm Holding, B.V., the,pan-Europea...d that they,have entered into a euro 10 million re...fund SpePharm,s acquisition of Dantrium(R) for Eur...le Pharmaceuticals. At the same,time, TVM Capital,...
(Date:8/20/2008)... VIENNA, Va., Aug. 20 /PRNewswire-USNewswire/ ...0 ranking of the fastest-growing private companies...T) services provider,MicroTech, ranks No. 285 on ... 2008 Inc. 500 list measures revenue growth from 2...U.S.-based, privately held, independent -,no subsi...
(Date:8/20/2008)... INDIANAPOLIS, Ind., Aug. 20 /PRNewswire-First... announced that it has completed the acquisition,o...n Diego-based,biotechnology company focused on dru...y. The completion of the deal followed today,s Spe...SGX stockholders voted in,favor of the merger agre...
(Date:8/20/2008)... Growth Fueled by Popularity with Seniors and ... Marketing, CAMBRIDGE, Mass., Aug. 20 /PRNewswi...hole Health (SWH), a voluntary health care plan fo...ng private company in the,United States., Part of...rowing,companies, SWH had revenue growth of 31,000...
Breaking Biology Technology:TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 2TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 3TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 4TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 5MicroTech Ranks No. 285 on Inc. Magazine's 2008 List of the 500 Fastest Growing Private Companies in America 2Lilly Announces Completion of SGX Acquisition 2Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US 2Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US 3
...d by the Circuit Court of Wisconsin in Milwaukee ...d businesses that acquired Microsoft software ov...ibute nearly $224 million back to them as part of ...against the software giant. , ,The notices are the...awsuits about whether Microsoft violated Wisconsin...
...rs is Japan. In this column, I have covered differ...y and biotech markets (3/10/03, 8/18/03, 3/28/05).... Bio-Jan 2006 Conference in September after a th...rticipate in the 30th anniversary celebration of t...ad started in Chicago and culminated in a series o...
...n will decide whether to change the current long-s... be patentable, an invention must not be "obvious"... it was created by the inventor, and any change in...mpact the ability to procure and enforce patents. ...riefs to appreciate the importance of this case: ...
...ate that the Greater Madison area, while a key U.S...ched the "critical mass" of talent, innovation, an...nts and achieve a state of sustained growth. , ,Bu...convened Tuesday to welcome an emerging drug disco...hern suburb of Madison, a different message emerge...
Other Biology Technology:Microsoft to distribute $224M as part of settlement 2Japan on the rebound: Implications for Midwest 2Japan on the rebound: Implications for Midwest 3Japan on the rebound: Implications for Midwest 4Japan on the rebound: Implications for Midwest 5Japan on the rebound: Implications for Midwest 6Japan on the rebound: Implications for Midwest 7Japan on the rebound: Implications for Midwest 8Japan on the rebound: Implications for Midwest 9Inventions could fall prey to Monday morning quarterbacking 2Inventions could fall prey to Monday morning quarterbacking 3Inventions could fall prey to Monday morning quarterbacking 4Caden Biosciences may signal critical mass 2
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11
Mouse monoclonal antibody raised against a partial recombinant TOPORS. Immunogen: TOPORS (NP_005793, 98 a.a. ~ 206 a.a) partial recombinant protein with GST tag. Accession Number: NM_005802
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5
...al recombinant NFKBIB. Immunogen: NFKBIB (AAH1...in with GST tag. Protein Sequence: EDGDTALHLAV...GAGLCVAERRGHTALHLACRVGAHACARA Accession: BC015...: 604495, GeneID: 4793 Lot Number: MM9511...
Biology Products: